105 related articles for article (PubMed ID: 38735729)
1. Symptomatic adverse events of chemotherapy in breast cancer patients:Using CTCAE, PRO-CTCAE, and EORTC QLQ-C30.
Arahori H; Kondo K; Imai Y; Bando T; Inoue H; Sasa S; Takizawa H
J Med Invest; 2024; 71(1.2):82-91. PubMed ID: 38735729
[TBL] [Abstract][Full Text] [Related]
2. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.
Taarnhøj GA; Kennedy FR; Absolom KL; Bæksted C; Vogelius IR; Johansen C; Velikova G; Pappot H
J Pain Symptom Manage; 2018 Sep; 56(3):421-429. PubMed ID: 29807157
[TBL] [Abstract][Full Text] [Related]
3. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
4. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study.
Kang D; Kim S; Kim H; Lee M; Kong SY; Chang YJ; Sim SH; Kim YJ; Cho J
JMIR Public Health Surveill; 2023 Mar; 9():e44105. PubMed ID: 36884274
[TBL] [Abstract][Full Text] [Related]
6. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova G; Morden JP; Haviland JS; Emery C; Barrett-Lee P; Earl H; Bloomfield D; Brunt AM; Canney P; Coleman R; Verrill M; Wardley A; Bertelli G; Ellis P; Stein R; Bliss JM; Cameron D;
Lancet Oncol; 2023 Dec; 24(12):1359-1374. PubMed ID: 37926100
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study.
; Mihaljevic AL
Ann Surg Oncol; 2021 Jun; 28(6):3075-3089. PubMed ID: 33683524
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia.
Liew AC; Peh KK; Tan BS; Zhao W; Tangiisuran B
Support Care Cancer; 2019 Dec; 27(12):4515-4524. PubMed ID: 30911917
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
[TBL] [Abstract][Full Text] [Related]
11. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
13. [Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
Gozzo Tde O; Moysés AM; da Silva PR; de Almeida AM
Rev Gaucha Enferm; 2013 Sep; 34(3):110-6. PubMed ID: 24344592
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
16. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
[TBL] [Abstract][Full Text] [Related]
17. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC
Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529
[TBL] [Abstract][Full Text] [Related]
18. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
[TBL] [Abstract][Full Text] [Related]
19. Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.
Fabbro M; Jacot W; Jarlier M; Guiu S; D'Hondt V; Pouderoux S; Champoiral P; Janiszewski C; Nicklès I
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1732. PubMed ID: 36302744
[TBL] [Abstract][Full Text] [Related]
20. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Taarnhøj GA; Johansen C; Lindberg H; Basch E; Dueck A; Pappot H
Cancer Med; 2020 May; 9(9):3078-3087. PubMed ID: 32154663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]